The use of fluoroquinolones in the treatment of skin infections

被引:7
作者
Martin, SJ [1 ]
Zeigler, DG [1 ]
机构
[1] Univ Toledo, Infect Dis Res Lab, Coll Pharm, Toledo, OH 43606 USA
关键词
antimicrobial resistance; ciprofloxacin; gatifloxacin; levofloxacin; moxifloxacin;
D O I
10.1517/eoph.5.2.237.26489
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluoroquinolones have been studied for both uncomplicated and complicated skin and skin structure infections. Their broad spectrum, rapid bactericidal activity, extensive tissue penetration, excellent bioavailability and ease of administration have made these drugs a common choice for many infectious diseases, including skin infections. Extensive research has shown the fluoroquinolones to be as effective as beta-lactam antibiotics in managing a spectrum of diseases including erysipelas, cellulitis, impetigo, surgical wounds and diabetic foot infections. However, resistance to the fluoroquinolones has increased among the staphylococci, streptococci, Enterobacteriaceae and other important Gram-negative bacilli. Resistance has been linked directly to the widespread use of these compounds. Despite their appeal in the treatment of both uncomplicated and complicated skin infections, the fluoroquinolones should be reserved as alternatives to beta-lactams and other antibiotics or as empirical therapy in complicated infections until pathogens have been identified and drug regimens can be focused.
引用
收藏
页码:237 / 246
页数:10
相关论文
共 54 条
  • [1] ANDRIOLE VT, 2000, QUINOLONES, P34
  • [2] BAYER AG, 2003, AVELOX MOXIFLOXACIN
  • [3] Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
    Blondeau, JM
    Laskowski, R
    Bjarnason, J
    Stewart, C
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 14 (01) : 45 - 50
  • [4] Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P800
  • [5] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    Chen, DK
    McGeer, A
    de Azavedo, JC
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
  • [6] Cohen FL, 1997, AM J INFECT CONTROL, V25, P51
  • [7] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [8] PHARMACOKINETICS AND TISSUE PENETRATION OF CIPROFLOXACIN
    CRUMP, B
    WISE, R
    DENT, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (05) : 784 - 786
  • [9] Fluoroquinolone adverse effects and drug interactions
    Fish, DN
    [J]. PHARMACOTHERAPY, 2001, 21 (10): : 253S - 272S
  • [10] PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS
    FORREST, A
    NIX, DE
    BALLOW, CH
    GOSS, TF
    BIRMINGHAM, MC
    SCHENTAG, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) : 1073 - 1081